Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Diabetes

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 56 articles:
HTML format
Text format



Single Articles


    September 2018

  1. Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;379:1181-1184.
    PubMed     Text format    


  2. RUSSELL MJ, Kanthimathinathan HK
    Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;379:1183.
    PubMed     Text format    


  3. WHITE PC
    Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;379:1182-3.
    PubMed     Text format    


  4. KAMEL KS, Carlotti APCP, Halperin ML
    Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;379:1181-2.
    PubMed     Text format    


    August 2018

  5. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
    N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1804989.
    PubMed     Text format     Abstract available



  6. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1804988.
    PubMed     Text format     Abstract available


  7. BOHULA EA, Wiviott SD, McGuire DK, Inzucchi SE, et al
    Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
    N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1808721.
    PubMed     Text format     Abstract available


  8. TRIPATHY K
    Asteroid Hyalosis.
    N Engl J Med. 2018;379:e12.
    PubMed     Text format    


  9. SCHROEDER SA
    Heavier but Healthier - Diabetes and Smoking Cessation.
    N Engl J Med. 2018;379:684-685.
    PubMed     Text format    


  10. HU Y, Zong G, Liu G, Wang M, et al
    Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality.
    N Engl J Med. 2018;379:623-632.
    PubMed     Text format     Abstract available


  11. RAWSHANI A, Rawshani A, Franzen S, Sattar N, et al
    Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    N Engl J Med. 2018;379:633-644.
    PubMed     Text format     Abstract available


  12. BALLY L, Thabit H, Hartnell S, Andereggen E, et al
    Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care.
    N Engl J Med. 2018;379:547-556.
    PubMed     Text format     Abstract available


  13. FENSKE W, Refardt J, Chifu I, Schnyder I, et al
    A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus.
    N Engl J Med. 2018;379:428-439.
    PubMed     Text format     Abstract available


  14. ROSEN CJ, Ingelfinger JR
    A Reliable Diagnostic Test for Hypotonic Polyuria.
    N Engl J Med. 2018;379:483-484.
    PubMed     Text format    


    June 2018
  15. CAN B, Can B
    Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
    N Engl J Med. 2018;378:2537.
    PubMed     Text format    


  16. CADWELL JB, Shukla AP
    Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
    N Engl J Med. 2018;378:2537.
    PubMed     Text format    



  17. Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
    N Engl J Med. 2018;378:2537-2538.
    PubMed     Text format    


  18. SPERLING MA
    Fluid Composition, Infusion Rate, and Brain Injury in Diabetic Ketoacidosis.
    N Engl J Med. 2018;378:2336-2338.
    PubMed     Text format    


  19. KUPPERMANN N, Ghetti S, Schunk JE, Stoner MJ, et al
    Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;378:2275-2287.
    PubMed     Text format     Abstract available


    April 2018
  20. BJERREGAARD LG, Jensen BW, Angquist L, Osler M, et al
    Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
    N Engl J Med. 2018;378:1302-1312.
    PubMed     Text format     Abstract available


    March 2018
  21. HUSEBYE ES, Anderson MS, Kampe O
    Autoimmune Polyendocrine Syndromes.
    N Engl J Med. 2018;378:1132-1141.
    PubMed     Text format    


  22. PAWAR AS, Kattah AG
    Lithium-Induced Nephropathy.
    N Engl J Med. 2018;378:1042.
    PubMed     Text format    


  23. KHOO TK, Olson KM
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:967.
    PubMed     Text format    


  24. DOUMAS M, Imprialos KP, Stavropoulos K
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:967.
    PubMed     Text format    


  25. CONTE C, Secchi A, Napoli N
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:966.
    PubMed     Text format    


  26. GOGTAY NJ, Bose D, Thatte UM
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:966.
    PubMed     Text format    



  27. Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:966-968.
    PubMed     Text format    


    February 2018
  28. FLYNN JT
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2018;378:580.
    PubMed     Text format    


  29. MEI ZB, Xiao Y
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2018;378:579.
    PubMed     Text format    


  30. JONNALAGADDA VG, Metety VK
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2018;378:579.
    PubMed     Text format    



  31. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2018;378:579-581.
    PubMed     Text format    


    January 2018
  32. AGARWAL A
    Evaluation and Management of Lower-Extremity Ulcers.
    N Engl J Med. 2018;378:302.
    PubMed     Text format    


  33. CEREDA E
    Evaluation and Management of Lower-Extremity Ulcers.
    N Engl J Med. 2018;378:301-2.
    PubMed     Text format    


  34. DI BELLA S, Monticelli J, Luzzati R
    Evaluation and Management of Lower-Extremity Ulcers.
    N Engl J Med. 2018;378:301.
    PubMed     Text format    


    December 2017
  35. IMPRIALOS KP, Stavropoulos K, Doumas M
    Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2502.
    PubMed     Text format    


  36. HOLMAN RR, Bethel MA, Hernandez AF
    Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2502.
    PubMed     Text format    


    November 2017
  37. THORNTON SN, Regnault V, Lacolley P
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2196-7.
    PubMed     Text format    


  38. IMPRIALOS KP, Stavropoulos K, Doumas M
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2196.
    PubMed     Text format    


  39. GULLI G
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2195-6.
    PubMed     Text format    


  40. TONNEIJCK L, van Raalte DH, Muskiet MHA
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2195.
    PubMed     Text format    



  41. Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2195-2199.
    PubMed     Text format    


  42. DE BOER IH
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2198.
    PubMed     Text format    



  43. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2097-2099.
    PubMed     Text format    


  44. RAJAGOPALAN S, Brook R
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2098-9.
    PubMed     Text format    


  45. FERNANDEZBALSELLS MM, Sojo-Vega L, Ricart-Engel W
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2098.
    PubMed     Text format    


  46. BAGLIONI P
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2097-8.
    PubMed     Text format    


  47. PERFETTI R
    Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1995.
    PubMed     Text format    


  48. TAYEK JA, Danese PNN, Smith MS
    Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1994-5.
    PubMed     Text format    


  49. OGUNSAKIN AA, Jain N, Dagogo-Jack S
    Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1994.
    PubMed     Text format    



  50. Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1995-1996.
    PubMed     Text format    


  51. MARCOVECCHIO ML, Chiesa ST, Bond S, Daneman D, et al
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2017;377:1733-1745.
    PubMed     Text format     Abstract available


    October 2017
  52. MATSUO T, Ishii N
    Acute Esophageal Necrosis.
    N Engl J Med. 2017;377:1378.
    PubMed     Text format    


    September 2017
  53. ADAMS TD, Davidson LE, Litwin SE, Kim J, et al
    Weight and Metabolic Outcomes 12 Years after Gastric Bypass.
    N Engl J Med. 2017;377:1143-1155.
    PubMed     Text format     Abstract available


  54. HOLMAN RR, Bethel MA, Mentz RJ, Thompson VP, et al
    Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017 Sep 14. doi: 10.1056/NEJMoa1612917.
    PubMed     Text format     Abstract available


  55. GARG SK, Henry RR, Banks P, Buse JB, et al
    Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
    N Engl J Med. 2017 Sep 13. doi: 10.1056/NEJMoa1708337.
    PubMed     Text format     Abstract available


  56. NATHAN DM
    Adjunctive Treatments for Type 1 Diabetes.
    N Engl J Med. 2017 Sep 13. doi: 10.1056/NEJMe1711296.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: